IO BIOTECH (IEU LS)
Partially disbursed · Denmark
Source: European Investment Bank (EIB)
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccine therapies based on an innovative proprietary technology platform. The project involves the development of an innovative immunotherapeutic cancer vaccine to treat melanoma. Because of its broad applicability, this vaccine could become the new standard of care in the treatment of cancer more
- Status
- Prospective
- Sector
- Government
- Location
- Denmark
- Updated
- 19 Nov 2026
- Source
- European Investment Bank (EIB)
ConstructChat
Ask ConstructChat about IO BIOTECH (IEU LS)
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | partially disbursed |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccine therapies based on an innovative proprietary technology platform. The project involves the development of an innovative immunotherapeutic cancer vaccine to treat melanoma. Because of its broad applicability, this vaccine could become the new standard of care in the treatment of cancer more broadly. |
Original sector | Industry |
Location
Country | Denmark |
Source
Source | European Investment Bank (EIB) |
URL |
More Details
Record type | Project |
Sector | Government |
Article published date | 2025-11-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
